Clinical trials
for patients

The aim of this trial is to obtain more information on the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of MEDI5752 and, also, to better understand the disease studied and the associated health problems.

The aim of the study is to evaluate the efficacy of sequential treatment with oral fosfomycin in patients diagnosed with prostatitis after 2 to 5 days of therapy with an antibiotic suitable for the microorganism isolated parenterally, also studying the pharmacokinetic parameters of oral fosfomycin, in order to find an effective and safe treatment regimen that improves the patient's quality of life, reducing the number of days of hospitalization and avoiding side effects.

The main objective of this study is to compare MK-2870 with chemotherapy with respect to PFS according to RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations.

The primary objective of this study is to evaluate the tolerability of xevinapant when added to weekly CRT with cisplatin in patients with locally advanced SCC of the head and neck.

The objective of the study is to test a new treatment for your condition. Your doctor has determined that TheraSphereTM is an appropriate therapeutic option for you. The study will determine whether it is safe to add the drugs known as durvalumab and tremelimumab in immunotherapy following treatment with TheraSphereTM and whether this addition improves the outcomes observed with TheraSphereTM as monotherapy.

The primary objective of the study is to investigate whether the study medication (vafidemstat) is effective in treating the negative symptoms of the disease, described above, as well as in treating the loss of cognitive function in patients with schizophrenia, and also if this medication is safe. The study also aims to learn more about the causes of the disease and how our body processes the study drug. It is known that there is genetic variability in the population (not associated with any dis...

The aim of this study is to determine the safety and tolerability of INCB099280 and investigate any potential effects of the drug on both individuals and cancer. Different doses of the study drug will also be tested to assess which dose is the safest or may work better in the participants.

The present study aims to evaluate whether the results of several commonly requested tests in the clinical laboratory are valid when using capillary blood and are comparable to venous blood.

The main objective of this trial is to test whether RO7589831 administered at different doses has effects (good or bad), as well as what happens to RO7589831 once it has entered the body and how it acts on the body and its disease.

We are conducting this trial to learn more about the drug Datopotomab-Deruxtecan (Dato-DXd) when used alone (monotherapy) and when used with other anticancer drugs (combination treatment).